Second suspected Nipah death in Kerala; tracing, surveillance stepped up
The man had been undergoing treatment at a private hospital in this northern district.
His samples were tested at Manjeri Medical College, where the result came back positive for Nipah, Health Minister Veena George said in a statement.
She added that the government is awaiting confirmation from the National Institute of Virology in Pune.
This is the second Nipah-related death reported in Kerala in recent days.
A native of Malappuram had recently died from the infection, while another patient from Palakkad district remains hospitalised.
In response to the fresh suspected case, the government has ramped up contact tracing and field-level surveillance in the area.
A list of 46 people who came into contact with the patient has been drawn up.
CCTV footage and mobile tower location data have been used to help identify those on the contact list. A detailed route map of the patient's recent movements has been prepared, along with a family tree to trace close contacts.
Health teams are now carrying out fever surveillance in the region to detect any possible symptoms in others.
'Field teams have been strengthened, and all available data is being used to monitor the situation,' George said.
Further steps will be taken once confirmation is received from the National Institute of Virology in Pune.
The minister has also instructed officials to step up the response team, considering the seriousness of the case.
Authorities have urged people in Palakkad and Malappuram districts to avoid unnecessary visits to hospitals, especially under the current circumstances.
Visits to friends or relatives receiving treatment should be strictly limited, officials said. Only one person is allowed to accompany a patient as an attendant.
Both healthcare workers and those coming to the hospital, including patients and their companions, are required to wear masks at all times, an official release said.
Meanwhile, the health minister also issued a Nipah alert to hospitals across six districts.
The advisory has been sent to medical facilities in Palakkad, Malappuram, Kozhikode, Kannur, Wayanad, and Thrissur. Hospitals have been directed to report any patients presenting with fever and symptoms resembling Nipah, including encephalitis and high-grade fever, the minister's office said.
According to the WHO, Nipah virus is a zoonotic disease that spreads from animals to humans and can also be transmitted through contaminated food or via direct human-to-human contact.
The Nipah virus contact list now includes a total of 543 people. Of these, 46 individuals are linked to the newly confirmed case, it said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
35 minutes ago
- India.com
What is Nipah Virus? Can it cause death? How it spreads? 7 ways to protect yourself
Nipah virus is transmitted to humans via contact or infected foods by animals. It leads to serious symptoms that are fatal and therefore prevention and hygiene is important. It is transmitted to humans from other animals such as bats or pigs and can cause death in infected people. The virus was discovered for the first time in Malaysia in 1999. It has since caused outbreaks in South Asia, and has been reported in countries such as India and Bangladesh. The virus can spread from an infected animal to a human if they have close contact with the animal's bodily orifices or consume infected fruits that the animal has contaminated. The symptoms of the virus consist of fever, headache, and respiratory issues. In severe cases of Nipah virus infection, death may occur and can cause brain inflammation, coma, and death. As of now, there is no vaccine or specific treatment for the virus. the only treatment is supportive care, and prevention is the best option. During outbreaks, try not to consume raw fruits or palm sap. Fruits eaten by bats can be contaminated with the virus, and that may be the reason for contamination. When in a situation where Nipah may be present, always use a mask, use sanitizer, and isolate situations when Nipah is suspected.
Hans India
2 hours ago
- Hans India
Over 14 mn children worldwide did not receive a single vaccine in 2024: UN
New Delhi: More than 14 million children worldwide did not receive a single dose of any vaccine in 2024, according to new national immunisation coverage data released on Tuesday by the UN agencies World Health Organization (WHO) and UNICEF. The report showed that nearly 20 million infants missed at least one dose of diphtheria, tetanus, and pertussis (DTP)-containing vaccine last year, threatening to unwind decades of progress. More than 30 million children also remained under-protected against measles, leading to more large or disruptive outbreaks. In 2024, the number of countries experiencing large or disruptive measles outbreaks rose sharply to 60, nearly doubling from 33 in 2022. The report blamed limited access to immunisation services, disrupted supply, conflict, and instability, or misinformation about vaccines for children remaining un or under-vaccinated. "Vaccines save lives, allowing individuals, families, communities, economies and nations to flourish," said WHO Director-General Dr. Tedros Adhanom Ghebreyesus. He noted that the missed doses were due to the 'drastic cuts in aid, coupled with misinformation about the safety of vaccines'. The report also noted that global childhood vaccination coverage held steady with around 171,000 more children receiving at least one vaccine compared to 2023, and one million more completed the full three-dose DTP series. In 2024, 89 per cent of infants globally -– about 115 million -– received at least one dose of the DTP-containing vaccine, and 85 per cent -- roughly 109 million – completed all three doses. Coverage against measles also improved, with 84 per cent of children receiving the first dose and 76 per cent receiving the second dose, which shows a slight increase from the previous year. An estimated 2 million more children were reached in 2024, but the overall coverage rate is far below the 95 per cent needed in every community to prevent outbreaks. 'The good news is that we have managed to reach more children with life-saving vaccines. But millions of children remain without protection against preventable diseases, and that should worry us all,' said UNICEF Executive Director Catherine Russell. Russell called on governments for increased determination "to overcome barriers like shrinking health budgets, fragile health systems along with misinformation and access constraints because of conflicts. No child should die from a disease we know how to prevent.' The report also raised concerns over falling national and global funding, growing instability worldwide, and rising vaccine misinformation that is threatening to further stall or even reverse progress made in the last several decades. This would risk increases in severe disease and deaths from vaccine-preventable diseases.
Time of India
3 hours ago
- Time of India
WHO recommends a twice-a-year injection for HIV prevention
The World Health Organization is now recommending that countries include a newly approved HIV drug for prevention, lenacapavir, as a tool in their efforts to fight HIV infections, especially for groups most at risk and in areas where the burden of HIV remains high. This landmark guidance, released at the 13th International AIDS Society Conference in Kigali on July 14 – as concern looms over funding for the global HIV fight – endorses the drug's use every six months, marking a pivotal shift from daily pills to long‑acting, needle‑delivered protection. What is Lenacapavir? Lenacapavir (brand names Sunlenca for treatment, Yeztugo for prevention) is a long‑acting capsid inhibitor that has redefined HIV prevention. Administered via injection just twice a year, it works by targeting the structural protein (capsid) of the HIV, blocking its ability to replicate in the body. Lenacapavir was approved in 2022 to treat certain HIV infections, and in trials for prevention, it was found to dramatically reduce the risk of infection and provide almost total protection against HIV. WHO's official recommendation Dr. Meg Doherty, director of WHO's Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, said in a news briefing, 'These new recommendations are designed for real-world use. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it legal? How to get Internet without paying a subscription? Techno Mag Learn More Undo WHO is working closely with countries and partners to support the implementation.' Doherty added, 'The first recommendation is that a long-acting injectable, lenacapavir, should be offered as an additional prevention choice for people at risk for HIV and as part of combination prevention. With that, we call it a strong recommendation with moderate to high certainty of the evidence.' The second recommendation in the guidelines is that rapid diagnostic tests, like at-home tests, can be used to screen someone for HIV when they are starting, continuing, or stopping long-acting medication to prevent infection, called pre-exposure prophylaxis, or PrEP. Health leaders, including WHO's Director‑General Dr. Tedros Adhanom Ghebreyesus, touted lenacapavir as 'the next best thing' to an HIV vaccine. This latest endorsement complements existing WHO‑approved prevention methods – daily oral PrEP, bi‑monthly cabotegravir injections, and the dapivirine vaginal ring. WHO also streamlined HIV testing protocols to support injectable PrEP uptake in community settings, pharmacies, and telehealth contexts. Why a twice‑yearly injection might prove to be a good shot Adherence and convenience: Daily pill demands consistency, which many at‑risk individuals struggle to maintain. Lenacapavir simplifies prevention to two clinic visits per year, helping sidestep barriers like stigma, pill fatigue, or limited healthcare access. Effectiveness: Purpose trial data speaks volumes: in one study, zero infections occurred among participants receiving lenacapavir, compared to significant infection rates in the pill‑based PrEP group. Equity and access: High‑risk populations – sex workers, LGBTQ+ individuals, people who inject drugs, incarcerated people, adolescents – stand to gain most from an easy‑to‑administer, long‑lasting prevention tool. What is HIV/AIDS? HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection, making a person more vulnerable to other infections and diseases. It is spread by contact with certain bodily fluids of a person with HIV, most commonly during unprotected sex (sex without a condom or HIV medicine to prevent or treat HIV), or through sharing injection drug equipment. If left untreated, HIV can lead to the disease AIDS (acquired immunodeficiency syndrome). Within a few weeks of HIV infection, flu-like symptoms such as fever, sore throat, and fatigue can occur. Then the disease is usually asymptomatic until it progresses to AIDS. AIDS symptoms include weight loss, fever or night sweats, fatigue, and recurrent infections. There is no existing cure for AIDS, but strict adherence to antiretroviral regimens (ARVs) can dramatically slow the disease's progress as well as prevent secondary infections and complications. Vaccines for HIV are under trial, but no effective vaccine has been developed to date. In early 2025, the global fight against HIV/AIDS faced a significant setback with the United States of America's decision to halt foreign aid funding for HIV prevention and treatment programs. This move, part of a broader 90-day pause in US foreign development assistance, sent shockwaves through the international health community only a week ago, raising alarms about a potential resurgence of the epidemic. WHO's endorsement of twice‑yearly lenacapavir marks a transformative moment, especially amidst the looming concerns regarding the funding cuts. Gilead Sciences, maker of lenacapavir, recently announced that it has reached an agreement with the nonprofit Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir for HIV prevention at no profit to the company. Under this agreement, Gilead's pricing reflects only the cost of producing and delivering lenacapavir. Gilead Chairman and CEO Daniel O'Day said in a news release, 'We are providing the medicine at no profit to Gilead, and in enough supply to reach up to two million people in low- and lower-middle-income countries ahead of generic lenacapavir becoming available.' Peter Sands, executive director of the Global Fund, said in the news release, lenacapavir can 'fundamentally change the trajectory of the HIV epidemic,' but only if it reaches the people who need it most. As per him, 'Our ambition is to reach 2 million people with long-acting PrEP. But we can only do that if the world steps up with the resources required. This is a pivotal moment — not just for the fight against HIV, but for the fundamental principle that lifesaving innovations must reach those who need them most — whoever they are, and wherever they live.' If scaled equitably and thoughtfully, this intervention could reshape the landscape of HIV prevention, moving us closer to a world without AIDS. Actor Nargis Fakhri Reveals 9‑Day Water Fast Twice a Year to Get 'Snatched'
